Allergan (NYSE:AGN) said today that it filed a de novo approval application with the FDA for its Oculeve nasal neurostimulation device for dry eye it bought last year. Oculeve is a hand-held device designed to be inserted into the nostril to stimulate the nerves serving the lacrimal gland. Allergan paid $125 million plus unspecified milestones for Oculeve last […]
Allergan’s Oculeve on track for FDA submission this year
Allergan (NYSE:AGN) said today that it’s on track for an FDA submission this year for the Oculeve nasal neurostimulation device for dry eye it bought last year. Oculeve is a hand-held device designed to be inserted into the nostril to stimulate the nerves serving the lacrimal gland. Allergan paid $125 million plus unspecified milestones for Oculeve last year. Today the […]
Allergan closes $125m Oculeve buy
Allergan said yesterday it closed its purchase of dry eye disease device developer Oculeve for $125 million in up-front payments in addition to unspecified commercialization milestones. South San Francisco-based Oculeve is developing a product called OD-01, a non-invasive nasal neurostimulation device designed to increase tear production in patients with dry eye disease, Allergan said. Oculeve has completed […]
Allergan to drop $125m on Oculeve
Allergan (NYSE:AGN) said today that it agreed to pay $125 million up front to acquire Oculeve and its dry eye disease device program, plus unspecified commercialization milestones. South San Francisco-based Oculeve is developing a product called OD-01, a non-invasive nasal neurostimulation device designed to increase tear production in patients with dry eye disease, Allergan said. A pair […]
Google Glass startup gains funding for flagship product | Medtech funding stories for the week of Mar. 17, 2014
Oculeve raises $16.6M in support of dry eye disease treatment
San Francisco startup Oculeve Inc. closed a $16.6 million funding round in supports of its implantable technology for treatment of dry eye disease.
Bidding war for Carestream heats up | Wall Street Beat
At least 5 major private equity players are vying for medical device company Carestream Health, including Bain Capital, Carlyle Group and KKR & Co., according to Reuters.
Onex Corp. is hoping to unload Carestream, formed in the 2007 spinout of Eastman Kodak Co.’s healthcare business, for up to $3.5 billion, the news service reported.
Cleveland HeartLab pulls in $15M | Wall Street Beat
Cleveland HeartLab pulled in $14.7 million in equity financing for its proprietary test for cardiac inflammation, according to a regulatory filing.
The CardioMPO test was developed by Dr. Stanley Hazen, director of the Cleveland Clinic’s center for cardiovascular diagnostics and prevention.
Cleveland HeartLab closed a $3 million round in 2010, with backers including Glengary and Second Generation Ltd.
MassDevice Network
@MassDevice
LinkedIn
YouTube